Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmarise Holdings Corp. ( (JP:2796) ) just unveiled an announcement.
Pharmarise Holdings reported consolidated net sales of ¥33.6 billion for the first half of the fiscal year ending May 31, 2026, up 10.0% year on year, with operating profit surging to ¥399 million and profit attributable to owners of parent recovering to ¥111 million from a loss a year earlier. The improvement in profitability, reflected in positive earnings per share of ¥9.75 and a higher equity ratio of 22.1%, positions the company for a strong turnaround in fiscal 2026, while management maintained full-year forecasts and plans to resume a year-end dividend of ¥14 per share, signaling confidence to shareholders despite a still-modest capital base.
The most recent analyst rating on (JP:2796) stock is a Hold with a Yen553.00 price target. To see the full list of analyst forecasts on Pharmarise Holdings Corp. stock, see the JP:2796 Stock Forecast page.
More about Pharmarise Holdings Corp.
Pharmarise Holdings Corporation, listed on the Tokyo Stock Exchange Standard Market, operates in Japan’s healthcare and pharmaceutical retail sector, focusing on pharmacy-related services and prescription drug sales. The company targets domestic medical and consumer markets through a network-based business model aimed at stable, recurring healthcare demand.
Average Trading Volume: 12,800
Technical Sentiment Signal: Sell
Current Market Cap: Yen6.12B
See more insights into 2796 stock on TipRanks’ Stock Analysis page.